Premium
Investigation of the mycobacterial enzyme HsaD as a potential novel target for anti‐tubercular agents using a fragment‐based drug design approach
Author(s) -
Ryan Ali,
Polycarpou Elena,
Lack Nathan A,
Evangelopoulos Dimitrios,
Sieg Christian,
Halman Alice,
Bhakta Sanjib,
Eleftheriadou Olga,
McHugh Timothy D,
Keany Sebastian,
Lowe Edward D,
Ballet Romain,
Abuhammad Areej,
Jacobs William R,
Ciulli Alessio,
Sim Edith
Publication year - 2017
Publication title -
british journal of pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.432
H-Index - 211
eISSN - 1476-5381
pISSN - 0007-1188
DOI - 10.1111/bph.13810
Subject(s) - mycobacterium tuberculosis , tuberculosis , mycobacterium bovis , enzyme , drug , recombinant dna , biochemistry , mutant , hydrolase , chemistry , biology , pharmacology , medicine , gene , pathology
With the emergence of extensively drug-resistant tuberculosis, there is a need for new anti-tubercular drugs that work through novel mechanisms of action. The meta cleavage product hydrolase, HsaD, has been demonstrated to be critical for the survival of Mycobacterium tuberculosis in macrophages and is encoded in an operon involved in cholesterol catabolism, which is identical in M. tuberculosis and M. bovis BCG.